Compare XERS & MRLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | MRLN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 915.1M |
| IPO Year | 2021 | 2024 |
| Metric | XERS | MRLN |
|---|---|---|
| Price | $6.89 | $6.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $25.00 |
| AVG Volume (30 Days) | 1.5M | ★ 3.5M |
| Earning Date | 05-07-2026 | 10-28-2021 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $690.00 | ★ N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.48 | $5.78 |
| 52 Week High | $10.08 | $17.00 |
| Indicator | XERS | MRLN |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 41.85 |
| Support Level | $5.81 | $6.05 |
| Resistance Level | $7.14 | $10.25 |
| Average True Range (ATR) | 0.25 | 0.97 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 81.50 | 9.53 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.